Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

NCT06648057 · clinicaltrials.gov ↗

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer
Cholangiocarcinoma

Interventions

DRUG: lenvatinib plus pembrolizumab

Sponsor

CHA University